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ABSTRACT. Background: Apart from waist circumference,
other adiposity measures, such as subscapular skin fold (SST),
arouse growing interest due to their relationship to metabol-
ic complications and cardiovascular risk. The IGF-I system is
deregulated in obese subjects in proportion to their degree
of visceral adiposity. Aim: To examine the association among
IGF-I, IGF-binding protein (BP)-1 and -3 levels and different
measures of adiposity in a sample of adult male population
in Southern Italy. Materials and methods: A complete
database for this analysis was available for 229 (age range
50-82 yr) participating at 2002-2004 Olivetti Heart Study
follow-up. Results: After adjustment for age, IGF-I was in-
versely associated with body mass index (BMI) and waist cir-
cumference (p<0.05). IGFBP-1 was inversely associated with
BMI, waist circumference, SST, homeostasis model assess-
ment (HOMA) index, fat mass. HOMA index, age, and SST
significantly predicted the IGFBP-1 plasma levels, with 24%
of IGFBP-1 variability explained at a linear regression anal-
ysis. Conclusions: IGFBP-1 inversely correlated to adiposity
and HOMA index. Among adiposity indexes, SST was the
best predictor of IGFBP-1 levels. The evaluation of some
components of the IGF system, and simple measures of body
adiposity, such as SST, may represent a further tool to bet-
ter evidence phenotype profiles associated to the patho-
genetic mechanism of cardiovascular risk factor clustering
in male adults.
(J. Endocrinol. Invest. 35: 925-929, 2012)
©2012, Editrice Kurtis
INTRODUCTION
Large epidemiological studies have evidenced that the
subscapular skinfold thickness (SST), a simple measure
of truncal subcutaneous fat, might represent a better and
more direct measure of body adiposity than body mass
index (BMI) (1, 2), although with a high variability de-
pending on differences in dietary intake and physical ac-
tivity (3). The influence of excess truncal subcutaneous
fat on insulin sensitivity has been reported to be similar
to that of waist circumference in some ethnic groups.
Thus, SST was also included as a defining anthropomet-
ric parameter of the metabolic syndrome (MS) in Asian
Indians, particularly in South Asians (4).
IGF-I as well as its most abundant binding proteins (BP)
IGFBP-1 and IGFBP-3, the main components of the IGF-
I system, are deregulated in proportion to the degree of
visceral adiposity (5-8). In that, a possible pathogenetic
role of IGF-I and its BP has been proposed in the past few
years in aging (9), obesity (10), insulin resistance (IR) (11)
and Type 2 diabetes (T2DM) (12, 13), MS (14, 15) and car-
diovascular disease (CVD) (16, 17). We also previously re-
ported that lower IGF-I levels, age-normalized, are asso-
ciated with increased prevalence of severe hypertension
and T2DM in a population of healthy subjects (18).
To our knowledge, there have been no attempts to eval-
uate the SST in an Italian population in relation to IGF
system in the setting of cardiovascular risk.
We took advantage of the Olivetti Heart Study (OHS)
database, an epidemiological investigation of metabolic,
nutritional, and genetic precursors of CVD in an occupa-
tional-based sample of an adult male population in
Southern Italy to examine the relationships among IGF-
I, IGFBP-1 and -3, anthropometric and biochemical pa-
rameters of MS.
MATERIALS AND METHODS
Population
The OHS population is given by the male workforce of the
Olivetti factories of Pozzuoli (Naples) and Marcianise (Caserta).
The general characteristics of the study and its methodological
procedures have been previously described (19, 20). The local
Ethics Committee approved the study protocol, and participants
provided their informed consent to participate. Among 994 sub-
jects (age range 32-82 yr) participating at Olivetti Heart Study,
examined between November 2002 and May 2004, a complete
database for IGF-I, IGFBP-1, and IGFBP-3 were available in 229
subjects.
A fasting venous blood sample was obtained for determination
of study biochemical variables. The blood specimens were im-
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mediately centrifuged and stored at –70 C until analyzed. Serum
glucose, total, HDL-, and LDL-cholesterol, triglycerides, creati-
nine were measured by automated methods (Cobas-Mira,
Roche, Milan, Italy). Serum insulin concentration was measured
by radioimmunoassay (Insulina Lisophase, Technogenetics, Mi-
lan, Italy). Insulin sensitivity was estimated by the homeostasis
model assessment (HOMA) index which is the product of fasting
plasma insulin (μU/ml) and fasting plasma glucose (mmol/l)/22.5,
as described by Matthews et al. (21).
Plasma IGF-I was measured by immunoradiometric assay after
ethanol extraction using Diagnostic System Laboratories Inc.
(Webster, Texas, USA). The International Reference Preparation
(IRP) used in the calibration of the IGF-I assay was WHO second
87/518. The sensitivity of the assay was 0.8 μg/l. The normal
IGF-I range 41-60, and over 60-yr-old subjects was 100-300, and
78-260 μg/l, respectively. The intra-assay coefficients of varia-
tion (CV) were 3.4, 3.0, and 1.5% for low, medium, and high
points on the standard curve, respectively. The interassay CV
were 8.2, 1.5, and 3.7 % for low, medium, and high points on the
standard curve, respectively. IGFBP-1 and IGFBP-3 levels were
measured by two enzyme-linked immunosorbent assay (Diag-
nostic System Laboratories Inc, Webster, Texas, USA). The IGF-
BP-1 assay had a sensitivity of 0.04 μg/l; the intra- and interas-
say CV were 9.6, 9.5, and 7.3% for the low, medium, and high
points of the curve, respectively; the interassay CV were 11.4,
10.4, and 8.2% for the low, medium, and high points of the
curve, respectively. IGFBP-3 reference values for adult male pop-
ulation were 1500-4600 μg/l. The IGF-I/IGFBP-3 ratio, an ap-
proximation of the free fractions of IGF-I, was estimated in order
to get a better understanding of the relative concentration
changes of IGF-I and IGFBP-3 levels. The values for the molec-
ular mass of IGF-I and IGFBP-3 used for the calculation were
7649 Da and 28 500 Da, respectively (22).
Anthropometric indexes
Body weight and height were measured on a standard beam
balance scale. Body weight was measured to the nearest 0.1 kg
and height was measured to the nearest centimeter. BMI was
calculated as weight (kg) divided by the height square (m2).
Waist circumference was measured at the umbilicus level with
the subject standing erect with the abdomen relaxed, arms at
the sides and feet together. The measurements were performed
to the nearest 0.1 cm with a flexible inextensible plastic tape.
SST was measured just below the inferior angle of the scapula at
45° to the vertical using a Lange skinfold calliper (Beta Tech-
nology Inc., Santa Cruz, CA, USA).
Bioelectrical impedance analysis
Body composition was determined by Bioelectrical Impedance
Analysis (BIA). Resistance and reactance were measured by a
single investigator with a single-frequency 50 kHz bioelectrical
impedance analyzer (BIA 101 RJL, Akern Bioresearch, Firenze,
Italy) according to the standard tetrapolar technique, with the
subject in supine position and the electrodes placed on the dor-
sal surface of the right foot and ankle, and right wrist and hand.
The body composition was calculated from bioelectrical mea-
surements and anthropometric data by applying the software
provided by the manufacturer, which incorporated validated
predictive equations for total body water, fat mass (FM) and free
FM, and extra-cellular water, while soft tissue hydration was eval-
uated as impedance vectors in the Resistance-Reactance Graph
by BIA Vector as previously reported (23).
Statistical analysis
Statistical analysis was performed using the Statistical Package
for Social Sciences (SPSS-PC version 11; SPSS Inc., Chicago, Illi-
nois, USA). As the distributions of age, insulin, HOMA index, de-
viated significantly from normality, they were normalized by log
transformation and log-transformed values were used in the
analysis. Results were expressed as means and range or 95%
confidence intervals (CI) unless otherwise indicated. Two-sided
p-values <0.05 were considered statistically significant. Multi-
ple linear regression analyses or analyses of covariance were
used to evaluate the relationship of various determinants with
IGF-I or IGFBP-1.
Linear regression analysis and analysis of covariance were used
to evaluate the relationship of anthropometric and biochemical
variables to IGFBP-1 levels, accounting for the effect of con-
founders.
RESULTS
The main characteristics of the study population are giv-
en in Table 1. Obesity, hypertension, and T2DM were re-
spectively present in 18.3%, 63.2%, and 14.0% of partic-
ipants. There were 9.2% of subjects with T2DM on cur-
rent treatment, of them two were treated with insulin.
The results were not affected by exclusion of these two
subjects from the analysis. There were not participants
affected by severe kidney failure (glomerular filtration rate
range from 30 to 115 ml/min according to Cockroft and
Gault formula) or severe liver impairment. A normal hy-
dration status was found in all the study participants ac-
cording to the BIA Vector analysis.
After adjustment for age, IGF-I plasma levels were in-
versely associated with BMI and waist circumference
(p<0.05) (Table 2). IGFBP-1 plasma levels were inversely
Table 1 - Characteristics of study population (no.=229*).
Mean Range
IGF-I (μg/l) 155.5 30.0-418.8
IGFBP-1 (μg/l) 16.7 0.14-133.4
IGFBP-3 (μg/l) 3868.8 1550-4620
Agea (yr) 61.6 50.1-81.6
Free fat mass % 75.2 64.1-83.7
Fat mass % 24.8 16.4-35.9
BMI (kg/m2) 27.1 18.8-35.7
Waist circumference (cm) 97.6 65.0-126.4
SST (mm) 21.7 7.8-43.2
Systolic blood pressure (mmHg) 138.2 99.0-192.0
Diastolic blood pressure (mmHg) 87.9 62.0-116.0
Total cholesterol (nmol/l) 57.05 2.69-8.13
HDL-cholesterol (nmol/l) 1.24 0.56-2.48
Triglycerides (nmol/l) 1.44 0.29-3.77
Fasting glucose (nmol/l) 5.63 3.66-15.65
Fasting insulina (mUI/ml) 9.1 1.6-38.3
HOMA indexa 1.9 0.89-15.5
The complete database among participants at Olivetti Heart Study ex-
amined between November 2002 and May 2004 (Ref. 19-20 in the text)
were available in 229 subjects.*Two diabetic participants were treated
with insulin. IGFBP1: IGF-binding protein-1; IGFBP3: IGF-binding pro-
tein-3; BMI: body mass index; SST: subscapular skinfold thickness; HOMA:
homeostasis model assessment. aLog-transformed values.
-0.5
Regression coefficient β (95% CI)
Free Fat Mass p=NS
Waist circumference p=0.033
BMI p=0.006
Subscapular skinfold p=0.001
-0.3 -0.1 0.1 0.3
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associated with BMI, waist, SST circumference, FM,
HOMA index, insulin (p<0.05). No significant associations
were observed with IGFBP-3 or with IGF-I/IGFBP-3 and
the study variables.
To evaluate the relative influence of adiposity’s measures
on IGFBP-1 plasma level accounting for potential con-
founders, each anthropometric factor was alternatively
introduced in a multiple linear regression equation with
age and HOMA index as covariates.
To allow a comparative evaluation of the effects of these
different factors on IGFBP-1, z-scores were calculated for
each factor and used for the analysis. The results of these
analyses are showed in Figure 1, which provides the
changes in IGFBP-1 plasma levels for 1-SD change in the
specified factors. Among the different measures of adi-
posity, after adjustment for potential confounders, SST
(p=0.001), BMI (p=0.006), and waist circumference
(p=0.033) were inversely and statistically associated to
IGFBP-1 levels.
To compare the relative predictive power of anthropo-
metric and metabolic factors associated with IGFBP-1,
we performed a stepwise multiple linear regression anal-
ysis using models that included as measures of adiposi-
ty SST (the best measure of adiposity associated with
IGFBP-1), along with all other variables found to be sig-
nificantly associated with plasma IGFBP-1. Using these
models, HOMA index entered at the first step and ap-
peared to be the factor exerting the most powerful in-
fluence on IGFBP-1, explaining 16% of IGFBP-1 variabil-
ity. Age entered at the second step, followed by SST.
The total proportion of IGFBP-1 variability explained by
these models was 24% (Table 3). The multiple linear re-
gression analysis was also performed according to the
BMI tertiles (Table 4). Probably due the small sample size
for each tertile of BMI, we are unable to find the relation
between SST and IGFBP-1 as reported in the whole pop-
ulation and also the relations with age and HOMA are
weaker than in the analysis using the whole study popu-
lation.
DISCUSSION
The complex regulation of the main components of the
IGF-I system is under the integrated control of GH, nu-
tritional factors, and glucose metabolism (12, 24). In par-
ticular, IGF-I and IGFBP-3, are part of the GH/IGF-I axis,
while IGF-I and IGFBP-1 are considered also components
of the obesity-IR axis, and are inversely associated with in-
sulin, BMI, and MS (5, 6, 8, 12).
Our data confirmed the inverse association between IGF-
BP-1 and IR in this unselected sample of adult male par-
Fig. 1 - Changes in IGF-binding protein (IGFBP)-1 plasma lev-
els for 1-SD change in the specified factors. Linear regression
analysis comparing different anthropometric measurements as
predictor of IGFBP-1 in study population. BMI: body mass in-
dex. IGFBP-1 values have been log transformed.
Table 2 - Correlations between anthropometric and metabolic
variables, IGF-I, IGF-binding protein (IGFBP)-1 and IGFBP-3.
Table 3 - Stepwise multiple linear regression analysis.
Table 4 - Stepwise multiple linear regression analysis according
to body mass index (BMI) tertiles. First tertile of BMI (no.=82).
Step Variable inserted p R2
First tertile of BMI (no.=82) [Variables excluded: STT and age]
1 HOMA indexa <0.001 0.12
Second tertile of BMI (no.=75) [Variable excluded: STT]
1 HOMA indexa 0.002 0.11
2 HOMA indexa 0.001 0.20
Age 0.002
Third tertile of BMI (no.=72) [Variables excluded: HOMA indexa and STT]
1 Age 0.014 0.071
Stepwise forward linear regression analysis: variation in plasma IGF-binding
protein-1 (IGFBP-1) levels explained by model with selected variables ac-
cording to BMI tertiles (no.=229). HOMA: homeostasis model assessment;
SST: subscapular skinfold thickness. aLog-transformed values.
Step Variable inserted p R2
1 HOMA index <0.001 0.16
2 HOMA index <0.001 0.21
Age <0.001
3 HOMA index <0.001
Age 0.001 0.24
SST 0.003
Independent variables: homeostasis model assessment (HOMA) index
(Log-transformed values), age, and subscapular skinfold thickness (SST).
Stepwise forward linear regression analysis: variation in plasma IGF-bind-
ing protein-1 (IGFBP-1) levels explained by model with selected variables
(no.=229).
IGF-I p IGFBP-1 p IGFBP-3 p
BMI (kg/m2) –0.146 0.028 –0.319 <0.001 0.076 ns
Waist circumference (cm) –0.142 0.033 –0.303 <0.001 –0.029 ns
SST (cm) –0.038 ns –0.310 <0.001 0.040 ns
Fat mass (%) –0.125 ns –0.171 0.010 –0.051 ns
HOMA indexa –0.102 ns –0.406 <0.001b –0.087 ns
Fasting insulina (mUI/ml) –0.087 ns –0.365 <0.001b –0.077 ns
alog-transformed values; bexpressed as Spearman rho coefficient. Corre-
lations between IGF-I system, anthropometric and metabolic measure-
ments in study population (no.=229). Bivariate correlations between vari-
ables accounting for age were examined using Pearson’s correlation co-
efficient and their values are singularly evidenced. BMI: body mass index;
SST: subscapular skinfold thickness; HOMA: homeostasis model assess-
ment.
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ticipants in the OHS, and evidenced that SST was the
best measure of adiposity associated with IGFBP-1. As
expected, waist circumference, BMI and FM exerted a
similar inverse effect on IGF-I levels, also after adjustment
for age. No significant associations were observed with
IGFBP-3 or with IGF-I/IGFBP-3 and the study variables.
To the best of our knowledge, the inverse correlation be-
tween IGFBP-1 and SST has not been reported before in
the setting of cardiovascular risk estimate in a Italian adult
male population.
A strong body of evidence shows that IGFBP-1 might be
considered a reliable laboratory biomarker of cardiovas-
cular risk (15, 16, 25) and insulin sensitivity, both in the
absence (26) and presence of T2DM (27). However, a
high variability in serum IGFBP-1 levels has been report-
ed among healthy individuals, with insulin as the prima-
ry determinant of IGFBP-1 expression both in vitro and in
vivo (28). In particular, insulin and IGF-I are considered
non-genetic factors responsible for 28% and 8% of the
variation in IGFBP-1 levels, respectively. In this context,
other variables such as diet and lifestyle habits and, per-
haps, body composition might be additional unexplained
factors accounting for the remaining variability in serum
IGFBP-1 levels. Large epidemiological studies in healthy
population have evidenced the inverse correlation IGFBP-
1 and visceral adiposity (29). However, no epidemiolog-
ical study has considered IGFBP-1 in relation to different
adipose tissue depots. Indeed, in addition to waist cir-
cumference (30), several investigators have emphasized
the importance of subcutaneous adipose tissue accumu-
lation, especially in the truncal and central regions, as a
contributory factor linked to the development of IR (31-
33). SST is a measure of truncal subcutaneous fat that has
been proposed as a better predictor of IR in subjects
from both Asian Indian (1) and Northern European pop-
ulation (2) than intra-abdominal adipose tissue. In our
study, beyond BMI and waist circumference, SST was the
best measure of adiposity associated with IGFBP-1. Al-
though at the stepwise multiple regression analysis
HOMA index was the best predictor of IGFBP-1 variabil-
ity, confirming the previous reported data, age and SST
entered at the second and third step, respectively, as ad-
junctive variables accounting for IGFBP-1 variability in
our series.
The relationship between IGF-I plasma concentrations
and body weight is non-linear, with positive association
in lean subjects, but an inverse relationship at higher BMI
levels (34). Obesity, and abdominal obesity in particular,
is associated with secondary depression of the GH-IGF-
I axis (7, 10). We previously reported that the prevalence
of IGF-I deficiency/insufficiency was up to 31% in a pop-
ulation of severely obese patients submitted to bariatric
surgery (35), being waist circumference and FM the ma-
jor determinants of IGF-I (23). Moreover, low IGF-I has
been associated with higher prevalence of cardiovascu-
lar disease and mortality (18), whereas high IGF-1 levels
tend to be associated with an increased risk for CV mor-
tality in an elderly population (36). The results of this
study provide further evidence that in adult males there
is inverse association of IGF-I with waist circumference,
BMI, and FM. However, although a strong association
has been reported between IGF-I/IGFBP-3 ratio and MS
(37) and anthropometric measures (5), we were not able
to find any association between body composition and
IGF-I/IGFBP-3 ratio. This finding was, however in keeping
with previous observations that IGF-I/IGFBP-3 ratio may
vary among populations (5, 38) and might have a scarce
usefulness in the assessment of MS in a population of
older men (15).
The main limitations of our study are the cross-sectional
nature of the data and of the study population, made on-
ly by male subjects, restraining our results to a similar
white male adult population. In addition, as the preva-
lence of T2DM and hypertension was different from that
of a healthy population, the data obtained in this study
should be interpreted with marked caution. Furthermore,
in obese patients, subtle variations of the hydration of
soft tissues can affect the accuracy of BIA in estimating
body composition. Nevertheless, as a normal hydration
was evidenced in all study participants, this eventuality
or the subsequent possible bias on the results of this
study could be minimized (39). Finally, taking into ac-
count the complex and integrated control of GH, nutri-
tional factors and glucose metabolism (25), the inclusion
of patients with T2DM, although <15%, could have in-
fluenced IGF-I axis status.
In conclusion, albeit not proving causal association, our
findings complemented previously published observa-
tions on the relationship between IGF system and IR and,
in addition, provided a link between the main compo-
nents of the IGF system and different measures of adi-
posity. Translating our results in clinical practice, these
data suggested that, adding to classical CVD risk factors
the evaluation of some components of the IGF system,
such as IGF-I and IGFBP-1, and simple measures of body
adiposity, such as SST, may represent a further tool to
better evidence phenotype profiles associated to the
pathogenetic mechanism of cardiovascular risk factor
clustering in male adults.
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